Improving cystic fibrosis treatment by targeting inflammation
Official title: Targeting inflammation to improve rescue of CFTR by modulator therapy
Funded at University of Kansas Medical Center · NIH-11057602 · Data updated 2026-11-12
This study is looking at how inflammation might impact the effectiveness of current cystic fibrosis treatments and whether adding a medication called losartan could help improve lung function and overall health for people with cystic fibrosis.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kansas Medical Center NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project start | May 18, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $170,452 |
| NIH project number | 5K23HL163445-03 |
| Project ID | NIH-11057602 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with cystic fibrosis who are currently receiving CFTR modulator therapy.
✕Less likely to help
Patients who do not have cystic fibrosis or those not on CFTR modulator therapy may not benefit from this research.
What this research studies
This research investigates how inflammation affects the effectiveness of CFTR modulator therapies in patients with cystic fibrosis (CF). It aims to explore the use of losartan, an anti-hypertensive medication known for its anti-inflammatory properties, to enhance the benefits of existing CF treatments. By analyzing nasal fluid samples from patients on modulator therapy, the study seeks to understand the relationship between inflammation and CFTR function. The goal is to identify new strategies that could improve lung function and overall health in CF patients.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for cystic fibrosis patients, enhancing their lung function and quality of life.
How similar studies have gone: Preliminary evidence suggests that targeting inflammation in cystic fibrosis may enhance treatment efficacy, indicating potential success for this approach.
Where this research is happening
-
University of Kansas Medical Center
Kansas City, United States Active
Researchers
- Principal investigator: Bengtson, Charles — University of Kansas Medical Center
- Study coordinator: Bengtson, Charles
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.